Palonosetron Hydrochloride | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Palonosetron Hydrochloride
HEALTH CANADA PATENTS

Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Contact Supplier

Jai Radhe Sales is your partner for all your sourcing needs.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

Contact Supplier

Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

Palonosetron Hydrochloride

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

40 API Suppliers, 22 USDMF, 3 JDMF, 9 EU WC, 4 KDMF, 13 NDC API, 24 Listed Suppliers, $ API Reference Price

40 API Suppliers
22 USDMF
3 JDMF
9 EU WC
4 KDMF
13 NDC API
24 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

11 Drugs in Development

11 Drugs in Development

INTERMEDIATES

11 Intermediates Suppliers

11 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

90 FDF Dossiers, 34 FDA Orange Book, 20 Europe, 2 Canada, 6 Australia, 7 South Africa, 21 Listed Dossiers

90 FDF Dossiers
34 FDA Orange Book
20 Europe
2 Canada
6 Australia
7 South Africa
21 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - 300MG;EQ 0.5MG BASE, SOLUTION;INTRAVENOUS - EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML), POWDER;INTRAVENOUS - EQ 235MG BASE/VIAL;EQ 0.25MG BASE/VIAL, SOLUTION;INTRAVENOUS - EQ 235MG BASE/20ML (EQ 11.75MG BASE/ML);EQ 0.25MG BASE/20ML (EQ 0.0125MG BASE/ML), INJECTABLE;INTRAVENOUS - EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INTRAVENOUS - EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - EQ 0.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE;ORAL - 300MG;EQ 0.5MG BASE
SOLUTION;INTRAVENOUS - EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)
POWDER;INTRAVENOUS - EQ 235MG BASE/VIAL;EQ 0.25MG BASE/VIAL
SOLUTION;INTRAVENOUS - EQ 235MG BASE/20ML (EQ 11.75MG BASE/ML);EQ 0.25MG BASE/20ML (EQ 0.0125MG BASE/ML)
INJECTABLE;INTRAVENOUS - EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
INJECTABLE;INTRAVENOUS - EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
CAPSULE;ORAL - EQ 0.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 Minakem, 2 Rochem International Inc, 15 SPI Pharma, 7 DKSH, 2 Jai Radhe Sales, 3 Faran Shimi Pharmaceutical, 3 Boai NKY Pharmaceuticals Ltd, 1 Chynops Pharma, 9 Gangwal Healthcare, 2 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 4 ACG Worldwide, 6 Actylis, 1 Alcedo Pharmachem, 6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 BASF, 3 DFE Pharma, 5 Gangwal Chemicals, 1 Ideal Cures Pvt Ltd, 2 Ingredion Pharma Solutions, 6 Kerry, 3 Lonza Capsugel, 9 Microlex e.U, 1 NEWEDGE Overseas, 2 Pharmatrans-Sanaq, 4 Pluviaendo, 4 Prachin Chemical, 1 Qualicaps, 22 Roquette, 5 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 2 Shijiazhuang Huaxu Pharmaceutical, 9 Sigachi Industries, 1 Ulanqab Kema New Material, 3 Vasa Pharmachem, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

49 Fillers, Diluents & Binders, 23 Direct Compression, 18 Lubricants & Glidants, 17 Thickeners and Stabilizers, 17 Disintegrants & Superdisintegrants, 14 Chewable & Orodispersible Aids, 14 Co-Processed Excipients, 14 Taste Masking, 11 Coating Systems & Additives, 11 Parenteral, 11 Film Formers & Plasticizers, 10 Granulation, 8 Empty Capsules, 7 Controlled & Modified Release, 3 Emulsifying Agents, 3 API Stability Enhancers, 2 Solubilizers, 2 Coloring Agents, 2 Rheology Modifiers, 1 Topical, 1 Soft Gelatin

49 Fillers, Diluents & Binders
23 Direct Compression
18 Lubricants & Glidants
17 Thickeners and Stabilizers
17 Disintegrants & Superdisintegrants
14 Chewable & Orodispersible Aids
14 Co-Processed Excipients
14 Taste Masking
11 Coating Systems & Additives
11 Parenteral
11 Film Formers & Plasticizers
10 Granulation
8 Empty Capsules
7 Controlled & Modified Release
3 Emulsifying Agents
3 API Stability Enhancers
2 Solubilizers
2 Coloring Agents
2 Rheology Modifiers
1 Topical
1 Soft Gelatin

DIGITAL CONTENT

2 DATA COMPILATION #PharmaFlow, 62 NEWS #PharmaBuzz

2 DATA COMPILATION #PharmaFlow
62 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 18 Finished Drug Prices, 10 Annual Reports

1 US Medicaid Prescriptions
18 Finished Drug Prices
10 Annual Reports

MARKET PLACE

7 APIs, 6 FDF Dossiers

7 APIs
6 FDF Dossiers

PATENTS & EXCLUSIVITIES

76 US Patents, 3 Health Canada Patents

76 US Patents
3 Health Canada Patents

REF. STANDARDS & IMPURITIES

7 USP, 7 Others

7 USP
7 Others

$ API Ref.Price (USD/KG) : 680,068 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

3 All

01 3Knight Therapeutics Inc

filter Patent Reset all filters

3 All

01 12505990

02 12514224

03 12666512

filter Product Reset all filters

3 All

01 1PALONOSETRON HYDROCHLORIDE

02 2Palonosetron Hydrochloride

filter Dosage Reset all filters

3 All

01 1CAPSULE

02 2solution

filter Exp Date Reset all filters

3 All

01 12023-11-06

02 12024-01-30

03 12027-10-19

Product Main Page

01

Knight Therapeutics Inc

Palonosetron

American Pharma Summit

Not Confirmed

Knight Therapeutics Inc

Country

American Pharma Summit

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2023-11-06

Date Granted : 2009-05-19

Palonosetron

Brand Name : ALOXI

Patent Number : 2505990

Filing Date : 2003-11-06

Strength per Unit : 0.05 mg / mL

Dosage Form : solution

Human Or VET : Human

Route of Administration : Intravenous

Patent Expiration Date : 2023-11-06

Date Granted : 2009-05-19

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

02

Knight Therapeutics Inc

Palonosetron

American Pharma Summit

Not Confirmed

Knight Therapeutics Inc

Country

American Pharma Summit

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2024-01-30

Date Granted : 2009-11-03

Palonosetron

Brand Name : ALOXI

Patent Number : 2514224

Filing Date : 2004-01-30

Strength per Unit : 0.05 mg / mL

Dosage Form : solution

Human Or VET : Human

Route of Administration : Intravenous

Patent Expiration Date : 2024-01-30

Date Granted : 2009-11-03

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

03

Knight Therapeutics Inc

Palonosetron

American Pharma Summit

Not Confirmed

Knight Therapeutics Inc

Country

American Pharma Summit

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-10-19

Date Granted : 2014-05-27

Palonosetron

Brand Name : ALOXI

Patent Number : 2666512

Filing Date : 2007-10-19

Strength per Unit : 0.5 mg

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2027-10-19

Date Granted : 2014-05-27

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
LOOKING FOR A SUPPLIER?